This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2010 Apr 8;362(14):1312-24.

doi: 10.1056/NEJMra0912522.

Oral phosphate binders in patients with kidney failure

Marcello Tonelli¹, Neesh Pannu, Braden Manns

Affiliations

PMID: 20375408
DOI: 10.1056/NEJMra0912522

Review

Oral phosphate binders in patients with kidney failure

Marcello Tonelli et al. N Engl J Med. 2010.

. 2010 Apr 8;362(14):1312-24.

doi: 10.1056/NEJMra0912522.

Authors

Marcello Tonelli¹, Neesh Pannu, Braden Manns

Affiliation

¹ Department of Medicine, University of Alberta, Edmonton, Canada. mtonelli-admin@med.ualberta.ca

PMID: 20375408
DOI: 10.1056/NEJMra0912522

No abstract available

PubMed Disclaimer

Comment in

Oral phosphate binders in patients with kidney failure.
Feith GW. Feith GW. N Engl J Med. 2010 Sep 2;363(10):989-90; author reply 990. doi: 10.1056/NEJMc1005274. N Engl J Med. 2010. PMID: 20809852 No abstract available.
Oral phosphate binders in patients with kidney failure.
Moe SM, Block GA, Langman CB. Moe SM, et al. N Engl J Med. 2010 Sep 2;363(10):990; author reply 990. doi: 10.1056/NEJMc1005274. N Engl J Med. 2010. PMID: 20830820 No abstract available.

Similar articles

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM. Sprague SM. Curr Med Res Opin. 2007 Dec;23(12):3167-75. doi: 10.1185/030079907X242719. Curr Med Res Opin. 2007. PMID: 17991307 Review.
Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Senatore M, Coppolino G, Papalia T, Greco R, Lofaro D, Bonofiglio R. Senatore M, et al. Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1352-4. Eur Rev Med Pharmacol Sci. 2011. PMID: 22195373 No abstract available.
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ. St. Peter WL, et al. Drugs. 2017 Jul;77(11):1155-1186. doi: 10.1007/s40265-017-0758-5. Drugs. 2017. PMID: 28584909 Review.
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA, Galani VJ, Shah PR. Prajapati VA, et al. Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8. doi: 10.4103/1319-2442.132167. Saudi J Kidney Dis Transpl. 2014. PMID: 24821148
Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM. Raggi P, et al. Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S31-40. doi: 10.2215/CJN.05880809. Clin J Am Soc Nephrol. 2010. PMID: 20089501 Review.

See all similar articles

Cited by

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I. Cozzolino M, et al. Curr Drug Metab. 2014;15(10):953-65. doi: 10.2174/1389200216666150206124424. Curr Drug Metab. 2014. PMID: 25658128 Free PMC article. Review.
Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.
Kendrick J, Chonchol M. Kendrick J, et al. Semin Dial. 2015 Nov-Dec;28(6):610-9. doi: 10.1111/sdi.12412. Epub 2015 Aug 17. Semin Dial. 2015. PMID: 26278462 Free PMC article. Review.
Starry-sky bowels.
Chang FM, Tarng DC, Yang CY. Chang FM, et al. Int J Colorectal Dis. 2018 Dec;33(12):1807-1808. doi: 10.1007/s00384-018-3173-9. Epub 2018 Oct 2. Int J Colorectal Dis. 2018. PMID: 30280253
Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
Molony DA, Parameswaran V, Ficociello LH, Mullon C, Kossmann RJ. Molony DA, et al. Kidney360. 2020 Mar 23;1(4):263-272. doi: 10.34067/KID.0000332019. eCollection 2020 Apr 30. Kidney360. 2020. PMID: 35372921 Free PMC article.
Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation.
Stevens KK, McQuarrie EP, Sands W, Hillyard DZ, Patel RK, Mark PB, Jardine AG. Stevens KK, et al. Int J Nephrol. 2011;2011:297070. doi: 10.4061/2011/297070. Epub 2011 Aug 9. Int J Nephrol. 2011. PMID: 21860794 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

Canadian Institutes of Health Research/Canada

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information